Table 1.

In vitro potency of MK-5172 and other macrocyclic protease inhibitors against a genotype/mutant panel in an HCV NS3/4A protease enzymatic assay

Genotype/mutant	Ki (nM)a
	MK-5172	Vaniprevir	Danoprevir	TMC435
gt1b	0.01 ± <0.01	0.05 ± 0.01	0.03 ± <0.01	1.49 ± 0.73
gt1a	0.01 ± 0.01	0.07 ± 0.03	0.06 ± 0.02	1.98 ± 0.23
gt2a	0.08 ± 0.02	0.85 ± 0.31	0.17 ± 0.07	31.7 ± 5.0
gt2b	0.15 ± 0.06	1.44 ± 0.52	0.79 ± 0.07	232 + 62
gt3a	0.90 ± 0.2	54 ± 4	11.1 ± 2.2	850 ± 58
gt1b R155K	0.07 ± 0.01	19 ± 2	4.3 ± 0.4	136 ± 15
gt1b A156T	5.3 ± 0.9	22 ± 2	0.36 ± 0.06	35.6 ± 6.2
gt1b A156V	12 ± 2	88 ± 15	1.52 ± 0.33	390 ± 6
gt1b D168V	0.14 ± 0.03	77 ± 27	0.67 ± 0.14	598 ± 71
gt1b D168Y	0.30 ± 0.04	120 ± 60	0.74 ± 0.20	169 ± 53

^aValues are means and standard deviations.